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Abstract 
 
Cardiovascular disease is one of the main causes of death worldwide. Vascular 
calcification is a risk factor that strongly contributes to disease progression and to 
which the vitamin-K dependent family of proteins (VKDPs) appear to play a major role. 
Gla-rich protein, or GRP, was the last member of the VKDPs to be identified and has 
been associated with ectopic calcification in tissues such as skin, vasculature and 
cartilage in cases of dermatomyositis and pseudoxanthoma elasticum, chronic kidney 
disease and osteoarthritis, respectively, suggesting a possible role in the development 
and/or regulation of pathological calcification. Matrix Gla protein (MGP), another 
VKDP, is a recognized inhibitor of soft tissue calcification. Although its inhibitory 
mechanism is still not completely understood, distinct studies reported the binding of 
MGP to bone morphogenetic proteins (BMPs), known bone formation promoters in 
both skeletal and vascular tissue, antagonizing its function. However, these 
mechanisms of action are not enough to explain the numerous reported cases of 
calcification in humans leading us to hypothesize GRP as one of the missing regulators 
of calcification in soft tissues. Considering the reported data on MGP-BMP-2 
interaction, and since an effect of BMP-2 on GRP expression has been previously 
demonstrated, we have focused in understanding the importance of GRP in 
calcification inhibition via interaction with MGP and BMP-2, either as a duplet or as a 
part of a larger protein complex. To further investigate these possibilities, we have 
engineered HEK293T cells to overexpress GRP and MGP and used their conditioned 
media in addition to recombinant BMP-2. Our immunoprecipitation assays 
demonstrate, for the first time, an interaction between GRP and BMP-2, supporting 
our hypothesis of GRP acting as a regulator of ectopic calcification via an interaction 
with BMP-2. Although our novel data indicate that GRP-BMP-2 interaction could be 
determining to vascular calcification, further functional studies will soon be performed 
to prove this hypothesis.  
Keywords: Vitamin K dependent proteins (VKDPs), Gla-rich protein (GRP), matrix Gla 
protein (MGP), bone morphogenetic protein-2 (BMP-2), vascular calcification. 
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Resumo      
 
A doença cardiovascular é uma das principais causas de morte no mundo. A 
calcificação vascular é um factor de risco que contribui para a sua progressão e para o 
qual as proteínas dependentes da vitamina K (VKDPs) parecem ter um papel 
determinante. A proteína rica em Glas (GRP), a última das VKDPs a ser identificada tem 
sido associada a vários casos de calcificação ectópica na pele, vasculatura e cartilagem, 
em casos de dermatomiose e pseudoxanthoma elasticum, doença crónica do rim e 
osteoartrite, respectivamente, sugerindo um possível papel na regulação da 
calcificação patológica. A proteína Gla da matriz (MGP), outra VKDP, é reconhecida 
como um inibidor da calcificação dos tecidos moles. Embora o seu mecanismo de 
inibição não seja completamente conhecido, diversos estudos mostram a sua ligação a 
proteínas morfogenéticas do osso (BMPs), conhecidas por promoverem a formação de 
osso nos tecidos esquelético e vascular, antagonizando a sua função. Contudo, estas 
proteínas e os seus mecanismos de acção não são suficientes para explicar os 
inúmeros casos de calcificação ectópica em humanos levando-nos a propor a GRP 
como um dos reguladores adicionais envolvidos na inibição da calcificação. 
Considerando a interacção MGP-BMP-2 e o efeito da BMP-2 na expressão da GRP em 
condrócitos de ratinho, focámo-nos em investigar a importância da GRP na inibição da 
calcificação através do estudo da interacção com a MGP e BMP-2, quer como um 
dupleto ou como parte de um complexo proteico. Para este efeito, sobre-expressámos 
a GRP e MGP em células HEK293T e o seu meio condicionado, ao qual se adicionou 
BMP-2 recombinante, foi usado em ensaios de imunoprecipitação. Os nossos 
resultados demonstram, pela primeira vez, uma interação entre a GRP e BMP-2, 
apoiando a nossa hipótese de que a GRP actua como um regulador da calcificação 
ectópica e que esta poderá ocorrer através da interacção com a BMP-2. Neste 
momento, estamos a desenvolver estudos funcionais que julgamos ser determinantes 
para provar a nossa hipótese original que foi fortemente reforçada com os resultados 
deste trabalho.  
 
Palavras-chave: Proteínas dependentes da vitamina K (VKDPs), proteína rica em Glas 
(GRP), proteína Gla da matriz (MGP), proteína morfogenética do osso-2 (BMP-2), 
calcificação vascular. 
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Resumo alargado 
 
Uma dieta pobre em micronutrientes é um problema que afecta não só países 
pobres como também os países mais desenvolvidos, conduzindo ao aparecimento de 
diversas doenças tais como anomalias ósseas, calcificação arterial ou doença 
cardiovascular, osteoartrite, doença crónica do rim (CKD) e cancro. 
A vitamina K é um micronutriente cuja principal função é actuar como um co-factor 
para a γ-glutamil carboxilase (GGCX), enzima responsável pela conversão dos ácidos 
glutâmicos (Glu) em ácidos glutâmicos γ-carboxilados (Gla). Estes resíduos apresentam 
elevada afinidade para o cálcio, essencial para as diversas funções biológicas da família 
de proteínas dependentes da vitamina K (VKDP). Durante a reacção de γ-glutamil 
carboxilação, a forma reduzida da vitamina K (KH2) é convertida na sua forma oxidada 
(KO) que, por sua vez, pode ser reciclada pela enzima epóxido reductase da vitamina K 
(VKOR), promovendo o início de um novo ciclo. No entanto, esta enzima pode ser 
inibida, no fígado, por antagonistas da vitamina K (VKA), como é exemplo a varfarina, 
utilizada de forma generalizada como anticoagulante no tratamento de problemas 
tromboembólicos arteriais ou venosos. 
As VKDPs são uma família de proteínas constituída por 16 membros, dos quais os 
mais conhecidos e melhor caracterizados são os factores de coagulação, cuja função é 
essencial à sobrevivência. No entanto, existem outros membros desta família, como 
são exemplo a osteocalcina (OC), proteína Gla da matriz (MGP) e a proteína rica em 
Glas (GRP), descritas como tendo um papel na remodelação óssea e prevenção da 
calcificação vascular e uma associação a diversas doenças relacionadas com a 
calcificação anormal de tecidos. 
A MGP, isolada pela primeira vez a partir do osso bovino, é reconhecida pela sua 
capacidade de inibir a calcificação de tecidos moles. A atribuição desta função à MGP 
tornou-se clara após estudos em ratinhos knock out (KO) para este gene. A calcificação 
massiva das artérias observada nestes animais é acompanhada por uma transição 
fenotípica das células vasculares do músculo liso (VSMCs) para células do tipo osteo-
condrocítico. O mesmo fenótipo é também observado em ratinhos tratados com 
varfarina, apontando assim para a importância da γ-carboxilação da MGP na inibição 
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da calcificação vascular. Embora, o mecanismo pelo qual a MGP exerce a sua função 
ainda não seja completamente conhecido, são apontadas duas principais hipóteses: i) 
ligação da proteína a iões ou cristais de cálcio que se encontram em excesso nos 
tecidos moles levando à sua libertação para a circulação; ii) ligação da MGP a proteínas 
conhecidas pelo seu papel na osteo/condrogénese, como as proteínas morfogenéticas 
do osso (BMPs), antagonizando a função das mesmas. Na verdade, vários estudos 
realizados confirmam a interacção entre a MGP e as BMPs 2, 4 e 7.  
A MGP tem sido associada a patologias humanas como são exemplo as 
pseudoxanthoma elasticum (PXE) e esclerose sistémica (Ssc), caracterizadas pela 
mineralização das fibras elásticas e calcificação da pele, respectivamente. Outro 
exemplo é a síndrome de Keutel, uma doença autossómica recessiva caracterizada por 
mutações no gene da MGP. Esta síndrome é caracterizada por uma calcificação 
anormal da cartilagem, estenose periférica pulmonar e hipoplasia facial leve mas, ao 
contrário do que acontece em ratinhos KO, os doentes vivem até à idade adulta e não 
têm calcificação arterial severa o que sugere o possível envolvimento de outros 
reguladores da calcificação neste processo. 
A GRP, inicialmente purificada da cartilagem calcificada do esturjão (Acipenser 
nacarii), foi a última das VKDPs a ser identificada. A principal característica estrutural 
desta proteína é o seu elevado número de resíduos Gla encontrados na sua forma 
matura (15 em humanos) que lhe confere a capacidade de ligação ao cálcio. A GRP tem 
sido associada com a calcificação ectópica, tendo já sido demonstrado em humano 
calcificação da pele, tecidos vascular e cartilagíneo em casos de dermatomyositis, 
pseudoxanthoma elasticum (PXE), doença crónica do rim, cancro e osteoartrite. 
A calcificação vascular é uma doença que afecta a população desde há mais de 5 
milhares de anos, que por si só é um factor determinante e independente de risco para 
a morte por doença cardiovascular. Existem dois tipos de calcificação vascular 
dependendo da sua localização: i) calcificação da camada íntima dos vasos ou 
calcificação aterosclerótica e ii) calcificação da camada média dos vasos ou esclerose 
de Monckeberg. A primeira é relacionada com factores de risco como hipertensão, 
inflamação ou dislipidémia, enquanto a segunda está muito mais associada com o 
envelhecimento, CKD e diabetes mellitus.  
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Durante muito tempo a calcificação vascular foi considerada uma consequência 
inevitável do envelhecimento, mas actualmente é considerada um processo activo que 
implica diferentes mecanismos moleculares de inibição onde as VKDPs podem 
desempenhar um papel fundamental. 
Os cristais de cálcio e fosfato são abundantes na circulação, podendo a sua 
deposição ser evitada devido à presença de inibidores específicos, como a MGP. Para 
esta proteína, foi demonstrado que o impedimento da deposição destes cristais 
depende da presença de resíduos Gla na sua estrutura. Quando o fornecimento de 
vitamina K é inadequado, ou quando são administrados antagonistas da vitamina K, a 
proteína MGP torna-se inactiva conduzindo a casos de calcificação ectópica. No 
entanto, existem indicações de que esta proteína não actua de forma independente: a 
presença da MGP num complexo com a fetuína-A e minerais de cálcio e fosfato foi 
descrito por diversos estudos, que sugerem um papel na prevenção da calcificação 
vascular através do impedimento da deposição de minerais, libertando-os para a 
circulação.   
Como acontece durante a osteogénese e condrogénese, as VSMCs libertam 
vesículas da matriz (MVs) que servem como local para a deposição de cristais de cálcio 
e fosfato promovendo a calcificação da matriz extracelular. Em condições normais, 
estas MVs possuem inibidores da calcificação, como a fetuina-A e MGP, que impedem 
este processo de deposição de cristais. Contudo, quando a quantidade de cálcio é 
elevada, como descrito em patologias associadas à calcificação vascular, estas MVs 
estão aptas a calcificar. Nos locais de calcificação vascular, as VSMCs podem sofrer 
uma alteração de fenótipo para células do tipo osteocondrocítico. Esta transição pode 
ser despoletada, por exemplo, pela BMP-2 que promove o aumento da expressão de 
factores osteogénicos essenciais para a transdiferenciação celular, tais como o Core-
binding factor subunit alpha-1/Runt-related transcription factor 2 (Cbfa/Runx2) e SRY-
related HMG box transcription factor 9 (Sox9). Como mencionado anteriormente, a 
MGP pode prevenir esta transição através da sua interacção com a BMP-2, impedindo 
a sua ligação aos receptores, bloqueando assim a transcrição normalmente promovida 
pela BMP-2. 
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Embora os estudos feitos indiquem a MGP como um inibidor da calcificação 
vascular, quer através da sua presença num complexo com a fetuína-A e minerais de 
cálcio e fosfato, quer através da sua ligação às BMPs, estes mecanismos não são 
suficientes para explicar o fenótipo associado a casos em que esta proteína está 
ausente. A presença de outros possíveis inibidores, sugerida recorrentemente na 
literatura, aliada aos conhecimentos que temos hoje levou-nos a propor a hipótese da 
GRP desempenhar esse papel. Deste modo, e considerando uma possível relevância da 
GRP no mecanismo de inibição da calcificação vascular, assim como o facto de 
tratamentos com BMP-2 em condrócitos de ratinho resultarem numa diminuição da 
transcrição da GRP, investigámos a possibilidade de regulação via interacção com a 
BMP-2. Assim, para estudar uma possível interacção entre GRP e BMP-2, começámos 
por sobre-expressar a GRP humana em células HEK293T tratadas com vitamina K. O 
mesmo desenho experimental foi utilizado para a produção de MGP humana, com o 
objectivo de ser usada como controlo positivo da interacção da BMP-2. Os resultados 
obtidos mostram a presença de GRP no meio condicionado ao contrário do que 
acontece com a MGP que fica maioritariamente retida no interior da célula e/ou na 
matriz extracelular e portanto pouco disponível no meio condicionado. Neste caso, é 
necessário proceder a optimizações do procedimento. Aos meios condicionados 
obtidos das HEK293T sobre-expressando GRP e MGP foi adicionada BMP-2 
recombinante e para testar a interacção entre as proteínas usaram-se técnicas de 
immunoprecipitação. Os resultados indicam uma ligação entre a GRP e BMP-2, 
reforçando o potencial papel da GRP na regulação da calcificação ectópica, através 
dum mecanismo semelhante ao utilizado pela MGP. Estudos funcionais com vista a 
esclarecer estas questões de forma mais aprofundada estão neste momento a ser 
desenvolvidos. 
Dado o envolvimento da GRP em diversas patologias onde a calcificação ectópica 
representa um risco determinante para a sua progressão, conhecer o seu mecanismo 
de acção será essencial para estabelecer esta proteína como um potencial alvo para o 
diagnóstico e até tratamento e/ou prevenção destas doenças. A co-localização destas 
três proteínas – GRP, MGP e BMP-2 – e a comparação entre tecidos patológicos e 
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saudáveis trará com certeza novas perspectivas para o mecanismo de acção da GRP e 
ajudará na avaliação do seu potencial como biomarcador.  
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1. Introduction 
 
1.1. The relevance of a micronutrient: Vitamin K 
The intake of micronutrients lower than recommended is widespread, not only in 
poor but also in developed countries, due to unbalanced diets rich in calories while 
deficient in micronutrients 1. Micronutrients insufficiency leads to their unbalanced 
usage: short-term survival functions have priority over to those that are less essential 
1. Consequently, persistent deficiency of micronutrients may cause age-related 
diseases, such as bone abnormalities, osteoarthritis, chronic kidney disease (CKD), 
cancer and cardiovascular disease 1.  
Vitamin K is a micronutrient which major function is to act as a cofactor for the γ-
glutamyl carboxylase (GGCX), an essential enzyme for the activation of vitamin K-
dependent proteins (VKDPs) biological function (Fig. 1.1) 2,3. VKDPs, initially described 
when studying coagulation cascade, namely coagulation factors II, VII, IX and X, are 
critical for short-term survival as shown by mice knockouts 1,2,4,5. Beyond  coagulation 
factors, there are other VKDPs, such as matrix Gla protein (MGP) and osteocalcin (OC), 
that although less critical for survival, when vitamin K supply is inadequate have long-
term consequences and may lead to age-associated conditions 1. 
Discovered by the Danish scientist Henrik Dam in 1930s, vitamin K belongs to a 
family of lipid-soluble vitamins that includes a common 2-methyl-1,4-napthoquinone 
ring 2,3,7. Depending on the structure of the substituted ring derivative, it can be 
classified in two biological active forms, vitamin K1 (or phylloquinone) and vitamin K2 
(or menaquinone, MK) that can be obtained from diet 8. While vitamin K1, the major 
form obtained by diet, is found in high concentrations in green leafy vegetables, 
vitamin K2 is found in fermented food such as cheese and Japanese natto, but can also 
be produced by intestinal bacteria in distal colon 3,5,6. There is also a third form, the 
synthetic vitamin K3 (or menadione), that needs to be converted into vitamin K2 to 
exhibit vitamin K activity 1,2,5.  
Dietary vitamin K is emulsified by bile salts to form micelles which are taken up by 
intestinal cells and incorporated into chylomicrons entering the blood stream and to 
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be transported to different target tissues 4. In spite of both forms being absorbed by 
small intestine, vitamin K1 is incorporated in lipoproteins enriched in triacylglicerol 
while vitamin K2 is transported by low and high-density lipoproteins (LDL and HDL, 
respectively) 10. Different tissue distribution is directly related to distinct transport 
mechanisms: whereas the vitamin K1 is mostly found in liver, vitamin K2 is distributed 
systemically through extra-hepatic tissues, and can actually be more active than 
vitamin K1 in these tissues 1,9. 
 
Figure 1.1 - The vitamin K cycle. Gamma-glutamyl carboxylase (GGCX) converts glutamate (Glu) into γ-
carboxylated glutamate (Gla) residues through conversion of reduced vitamin K (KH2) to vitamin K 
epoxide (KO). In order to be reused, KO is recycled by vitamin K epoxide reductase (VKOR) which can be 
inhibited by warfarin. Adapted from Willems et al (2014)8. 
 
1.2. VKDPs and the importance of vitamin K recycling  
Vitamin K dependent proteins become functional after being γ-carboxylated by the 
γ-glutamyl carboxylase (GGCX) enzyme that is localized in the endoplasmatic reticulum 
(ER) membrane 11. This enzyme is responsible for the conversion of glutamic acid (Glu) 
into γ-carboxylated (Gla) residues which exhibit high affinity for calcium ions and 
calcium crystals, a property being intimately related to VKDPs specific functions 11. The 
reduced form of vitamin K (KH2) is used by the GGCX as a co-factor for γ-glutamyl 
carboxylation 3. During this reaction, KH2 is converted into vitamin K epoxide (KO) that 
can be recycled by the vitamin K epoxide reductase (VKOR) enzyme promoting the 
beginning of new cycle  (Fig. 1.1) 12. This recycling enzyme can be inhibited in liver by 
vitamin K antagonists (VKA), such as 4-OH coumarin analogs (e.g. warfarin) widely used 
in anticoagulant therapies for the treatment of arterial and venous thromboembolic 
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disorders (Fig.1.1) 3,14,15. In these cases, and when vitamin K concentrations are 
increased, an alternative pathway occurring in liver, independent of coumarins, can be 
used to provide the γ-carboxylation cofactor. This pathway uses NAD(P)H 
dehydrogenases (DT-diaphorases) to reduce vitamin K 13.  
Vitamin K dependent proteins constitute a family of 16 described members – Table 
1 9. The most well-known VKDPs are coagulation factors such as prothrombin (factor 
II), factors VII, IX and X, and anticoagulation factors such as proteins C,  S and Z, that 
are synthesized mostly in liver with the exception of protein S 10,14,15.  
 
Table 1 – List of described VKDPs 1, 9 
 Protein Tissue of 
γ-carboxylation Function 
 
 
Coagulation 
Factor II 
(prothrombin) Liver, limited extra-hepatic 
Coagulation, regulation of 
inflammation 
Factor VII 
Coagulation Factor IX Liver Factor X 
Anticoagulation 
Protein C Liver Coagulation and anti-inflammatory regulation 
Protein S Liver and endothelial cells 
Coagulation, anti-inflammatory, 
phagocytosis and apoptosis 
Protein Z Liver Degradation of factor Xa 
 
 
 
 
Bone/vascular 
related 
Osteocalcin Primarily osteoblasts Bone homeostasis 
Matrix Gla protein 
Bone, cartilage, 
vascular tissues and 
macrophages 
Inhibitor of vascular 
calcification 
Gla-rich Protein Most soft tissues, cartilage Regulator of mineralisation 
Growth arrest 
specific gene 6 
(Gas6) 
Vascular smooth 
muscle cells 
(VSMCs) and 
endothelial cells 
TYRO3, AXL, and MER receptors 
(TAM) activating ligand 
Other VKDPs 
Transforming 
growth factor 
(TGF-α) inducible 
protein Most soft tissues 
Cell proliferation 
Proline-rich Gla 
protein Unknown Transmembrane 
Gla protein 
Periostin 
Bone marrow, 
mesenchymal 
stromal cells, 
cardiomyocytes 
 Collagen assembly and 
homeostasis 
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Other members of this family of proteins were identified and shown to be 
synthesized in extra-hepatic tissues, with widespread physiologic activities such as 
regulation of bone turnover, prevention of vascular calcification and apoptosis 10,14. 
Osteocalcin, MGP, GRP and growth arrest specific gene 6 protein (Gas6) can be 
included in this group of proteins, exhibiting highly specific physiologic functions – 
Table 1 10,14. 
VKDPs exhibit a general structural homology: a signal peptide, a propeptide and a 
mature protein that contains the Gla domain (Fig 1.2A) 13,16. The signal peptide is 
required for protein translocation into the ER where VKDPs bind to carboxylase 16. The 
propeptide contains the GGCX recognition site being shown to play an important role 
in the γ-carboxylation of these proteins 13,16,17. After carboxylation, all known VKDPs 
are released from the ER and directed to the Golgi, where the propeptide is further 
processed by the endopeptidase furin (with the exception of MGP, Fig. 1.2B) 13.  
 
 
Figure 1.2 - Vitamin K dependent proteins (VKDPs) general structure and processing. A) General 
structure of a VKDP. VKDPs are composed by a signal peptide (SP), a propeptide (Pro) that contains the 
GGCX recognition site and a mature protein (MP) including the Gla domain. B) VKDPs cellular processing: 
SP is required for protein translocation into the endoplasmatic reticulum (ER) where VKDPs bind to 
GGCX and γ-carboxylation occurs. After carboxylation, VKDPs are released into the Golgi, where the Pro 
is further processed by furin. Mature VKDPs (MP) are then released to the extracellular matrix where 
they can exert their specific function. Adapted from Bristol et al (1996) 18 
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1.3. Matrix Gla protein and Gla-rich protein: complementary 
partners (in health and disease)?  
 
1.3.1. Matrix Gla protein 
Matrix Gla protein was identified for the first time in 1983 in bovine bone  by 
Price and co-workers 19. It was the second Gla protein to be isolated from bone and 
demonstrated to be strongly associated with collagenous bone matrix 19. Despite its 
high accumulation in extracellular matrix (ECM) of bone, this protein is also 
synthetized in other tissues such as cartilage, lung, kidney, heart, arterial vessel wall 
and in calcified atherosclerotic lesions 19–22. MGP was also identified in rat, shark, 
chicken, xenopus and human, either as protein or as mRNA 23–26. 
1.3.1.1. Protein and gene structural characterization 
MGP is a small secreted VKDP that can undergo two types of post-translational 
modifications, γ-carboxylation and phosphorylation 27. The human mature protein 
consists of 89-aa, with a molecular weight of 14 kDa; five out of the nine Glu residues 
can be γ-carboxylated while three of its five serine residues can be phosphorylated 27. 
The human MGP gene is located on chromosome 12 (p13.1 - p12.3) and consists of 
four exons and three large introns with a total length of 3.9 kb (Fig. 1.3A) 27.  
Matrix Gla protein share common features with other VKDPs, such as a signal 
peptide, a mature protein containing the Gla domain, a AXXF motif and a RXXR furin-
like cleavage site (Fig. 1.3B) 16. In MGP the GGCX recognition site, although included in 
its propeptide, is not cleaved after the γ-carboxylation reaction and therefore is 
integrated in the mature protein, a feature that is unique among VKDPs 2,27. 
Additionally, MGP has a motif (Ser-X-Glu) recognized for serine phosphorylation 27. 
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Figure 1.3 - Structural organization of MGP at gene and protein levels. A) Gene structure of MGP. 
Boxes represent coding exons and orange boxes represent exons coding for the Gla domain. B) 
Illustration of MGP protein structure: SP, signal peptide; MP, mature protein; P, serine phosphorylation; 
GGCX, γ-glutamyl carboxylase recognition site; AXXF, proteolytic cleavage site in MGP; Gla, gla domain. 
Adapted from Viegas et al (2008) 28. 
 
1.3.1.2. MGP, the calcification inhibitor 
The function of MGP as an inhibitor of soft tissue calcification just became clear 
after studies in MGP null-mice 29. These animals died six to eight weeks after birth due 
to an extensive calcification that caused rupture of the thoracic and/or abdominal 
aorta 29. Moreover, the authors demonstrated a phenotypic transition in vascular 
smooth muscle cells (VSMCs) to chondrocyte-like cells 27,28. A phenotype similar to 
MGP null-mice was obtained after treatments with warfarin, with rats developing 
massive calcification of their cartilage, arteries and heart valves 29,30, demonstrating 
that the capacity of MGP to inhibit calcification is dependent of its γ-carboxylation 
status 31. 
The precise molecular mechanism by which MGP exerts its function is not yet 
completely understood but has been proposed to be through binding of calcium ions 
or calcium crystals present in excess in soft tissues and clearance into circulation 32.  
Supporting this hypothesis is the fact that MGP mRNA is expressed in many tissues 
while the protein usually accumulates in sites of ectopic calcification and circulates in 
plasma 32. To confirm these facts Roy and Nishimoto showed that MGP binds to 
increasing concentrations of hydroxyapatite (HA), further suggesting a binding site for 
HA in MGP. Moreover, Hackeng and colleagues demonstrated a Ca2+ binding to MGP 
and consequently a possible conformational change in protein’s structure 26,32. It was 
also suggested that MGP could antagonize proteins known to have a role in 
chondrogenesis and bone formation, such as bone morphogenetic proteins (BMPs), an 
issue that will be further discussed in this section 34.          
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Because MGP is poorly soluble in its mature secreted form, it was though that 
this protein circulates either in an aggregated form or bound to higher molecular 
weight chaperones 32. Price and co-workers were the firsts to identify MGP as part of a 
protein-mineral complex composed by hydroxyapatite, fetuin-A and other proteins in 
serum of rats treated with bisphosphonate etidronate, an inhibitor of bone 
mineralization 35. Nishimoto and colleagues, showed that MGP binds to vitronectin 
which is a multifunctional plasma and ECM protein with a role in cell adhesion, 
complement activation, coagulation and fibrinolysis 36. This interaction was proved to 
occur in vitro by colocalization and immunolocalization studies and may be a 
mechanism to anchor MGP to the ECM that could modify its activity 36. This group has 
also identified a binding site for vitronectin in a region flanking MGP C-terminus 36.  
 
1.3.1.3. MGP-related disorders 
Matrix Gla protein has been associated to several human disorders, such as 
pseudoxanthoma elasticum (PXE) and systemic sclerosis (Ssc) characterized by elastic 
fibres mineralization and skin calcification, respectively 36,37. Two different studies 
investigating MGP protein accumulation, both in dermis sections from PXE and skin 
biopsies from Ssc patients, respectively, have shown that MGP is more abundant in 
calcified tissues of these patients when compared to healthy controls 36,37. MGP has 
also been associated in cases of vascular calcification. For example, a study 
demonstrates, by immunohistochemistry, that undercarboxylated MGP (ucMGP) is 
strongly associated with intimal and medial calcification 39.  
The  Keutel syndrome, a human autosomal recessive disorder is characterized by 
mutations on MGP gene predicting the production of a non-functional protein 40. This 
syndrome is characterized by abnormal cartilage calcification, peripheral pulmonary 
stenosis and mild facial hypoplasia 40. Unlike the mouse model, Keutel patients survive 
until adulthood and lack  severe arterial calcification suggesting the involvement of 
alternative calcification regulators 40.  
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1.3.2. Gla-rich protein 
Gla-rich protein (GRP), also known as upper zone of growth plate and cartilage 
matrix associated protein (UCMA41,42), firstly isolated from the calcified cartilage of 
Adriatic sturgeon (Acipenser nacarii), was the latest VKDP to be discovered 28. This 
protein is highly conserved amongst vertebrates and exhibits two paralogs, GRP1 and 
GRP2, in teleost fishes, whose existence might be explained due to a genome 
duplication event 28,43. 
1.3.2.1. Protein and gene structural characterization 
GRP is a small secreted protein, negatively charged although highly insoluble at 
neutral pH 28. The protein exhibits a VKDP general protein structure, as previously 
mentioned in section 1.1.1 (Fig. 1.4A) 28. Sturgeon mature GRP, purified from calcified 
cartilage, was shown to be a 74-aa long protein, exhibiting a molecular weight of 10.2 
kDa where all its Glu residues were experimentally shown to be γ-carboxylated 28. Its 
gene structure is also highly conserved amongst species, comprising four introns and 
five exons 28. Exons 3, 4 and 5, all containing putative Gla residues, code for the mature 
protein but exon 4, by exhibting the larger number of Gla residues, is considered to be 
the functional core of the protein 28.  
Although its highly conserved gene structure, GRP alternative transcription 
appears to be species-specific (Fig. 1.4B). In murine embryo chondrocytes, during 
development, four distinct transcripts of GRP gene were reported, as well as in the two 
zebrafish paralogs 40,41. In both species, GRP-F1 is the longest and most abundant 
transcript; the other three, GRP-F2, GRP-F3 and GRP-F4, lack exon 2, exon 4 or both, 
respectively 44. Overexpression of mouse GRP isoforms, in HeLa cells, evidenced that 
GRP-F1 and GRP-F3 are secreted proteins that were localized, and detected by 
immunofluorescence, in the Golgi apparatus 44. On the contrary,  GRP-F2 and GRP-F4 
isoforms are not secreted, once they lost exon 2 they lack the signal peptide, and 
aggregate in a structure similar to the aggresome 44. Since exon 4 comprises most of 
the Gla residues, these transcripts give rise to two isoforms missing 60% of the 
putative Gla residues most possibly affecting protein function 44.  
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Recently, Rafael and colleagues identified in human osteoarthritis (OA) cartilage 
two novel alternatively spliced variants of human GRP gene, GRP-F5 and GRP-F6,  and 
a new alternative transcript in cartilage from wild-type murine femurs, GRP-F7 45. The 
two novel human transcripts, both GRP-F5 and GRP-F6, lack exon 3 leading to the loss 
of furin-like cleavage site for propeptide processing and GGCX recognition site 45. GRP-
F6 also lacks exon 2 leading to the translation of  a protein with shortening signal 
peptide length 45. Using an overexpression system in HEK293T cells, it was 
demonstrated that the new human protein isoforms, GRP-F5 and GRP-F6 are both 
secreted but GRP-F6 is secreted later than GRP-F5 since this transcript have a shorter 
signal peptide, pointing to a lower secretion potential and efficiency during secretory 
process 45.  
In terms of tissue distribution, at the transcriptional level, human GRP-F1 
alternative spice variant is ubiquitously expressed in foetal and adult tissues whereas 
GRP-F5 and F6 are mostly present in foetal tissues 45. These data suggest  that the 
biological function of splice variants should be further evaluated, specially throughout 
development 45.  
 
Figure 1.4 - GRP protein structure and splice variants. A) Protein structure of GRP. SP, signal peptide; 
Pro, propeptide; GGCX, γ-glutamyl carboxylase recognition site; AXXF, proteolytic cleavage site; RXXR, 
furin-like cleavage site; MP, mature protein. B) GRP-splice variants. Boxes represents coding exons and 
red boxes represents absent exons in each variant. Adapted from Rafael et al (2014)45.   
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1.3.2.2. Novel protein: old function? 
The main characteristic of GRP is its high number of Gla residues found in its 
mature protein form (15 putative Gla residues in humans) conferring it the highest Gla 
residues/protein size ratio 46. This feature has been conserved over 450 million years 
of evolution, with an impressive conservation degree in number and position of Glu 
residues as well as in its binding site for GGCX 28. This high density of Gla residues 
indicates a high calcium binding capacity for GRP, a function that has been extensively 
shown for other VKDPs 46. Nevertheless, the Gla capacity to bind calcium can confer 
different functions to distinct proteins, whether it is related to the coagulation cascade 
or involved in physiological or pathological mineralization of tissues, such as in case of 
vascular calcification 14.  
Gla-rich protein was found to be associated with ectopic calcification in human 
skin, vascular and cartilaginous tissues in cases of dermatomyositis, PXE, CKD, cancer 
and OA 46,47. Although experimental data demonstrating GRP degree of carboxylation 
in humans is still not available, the use of conformational antibodies, specific to 
carboxylated GRP (cGRP) and undercarboxylated GRP (ucGRP) protein forms, 
respectively, indicates a different pattern of association of these two forms to healthy 
or pathological conditions 47. Two studies demonstrated a preferential association of 
ucGRP with pathological situations, in cases of osteoarthritis and skin and breast 
cancers, while cGRP is more prevalent in corresponding healthy tissues 45,47. It was also 
demonstrated the colocalization of cGRP and ucGRP at sites of microcalcifications, 
suggesting that both forms have affinity to bind calcium, while the colocalization of 
both antibodies indicates an incomplete γ-carboxylation in healthy conditions 47.  
Different studies indicate that the role of GRP remains to be further clarified. 
Although at first GRP expression cannot be confirmed in no other tissues than in mice 
cartilage, later it was shown that GRP is expressed in rat and human skeletal tissue and 
that is accumulated in soft tissues, such as skin and the vascular system 43,45,46. 
Eitzinger and colleagues show that GRP-deficient mice have a normal development 
where no skeletal abnormalities or calcification of cartilage and bone is identified, 
indicating that this protein is not essential for normal cartilage development and 
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endochondral ossification 48. Nevertheless, the authors point to a possible phenotype 
related to calcification and bone turnover during pathological conditions and/or later 
in development 48. In contrast, in zebrafish, the knockdown of GRP1 leads to severe 
growth retardation and abnormal skeletal development and a similar phenotype 
occurs when γ-carboxylation is inhibited by warfarin 49. These results show that GRP1 
and the γ-carboxylation of its Glu residues are crucial for zebrafish skeletal 
development 49. These contradictory data may be partially explained by the finding 
that GRP1, in zebrafish, is earlier expressed than its murine orthologue 48.  
 
1.4.  Bone Morphogenetic Proteins 
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that 
belong to the transforming growth factor-beta (TGF-β) superfamily of proteins 50. 
These molecules were discovered by Dr. Marshal Urist in the 1960s and since then 
twenty BMP family members have been identified 50.  
BMPs are synthesized as large precursors consisting of a i) signal peptide, which 
directs the protein to the secretory pathway; ii) a prodomain, that mediates proper 
folding and iii) the mature peptide 50,51,52. After signal peptide cleavage, prodomain 
undergoes glycosylation and dimerization followed by proteolytical cleavage of the 
mature protein that becomes active 50. Active BMPs are composed by 50-100 amino 
acids among which seven cysteines, where six are used to form intramolecular 
disulphide bonds while the seventh forms a covalent disulphide bond with another 
monomer and is secreted as a dimer 51.  
Although primarily known for their capacity to induce ectopic bone formation, 
BMPs have a role in a variety of cell functions 50. These proteins are well known to act 
in mesenchymal stem cells differentiation and consequently leading to bone and 
cartilage formation, but are also involved in other diverse processes such as 
embyogenesis, organogenesis and tooth morphogenesis, cell proliferation and 
differentiation, apoptosis, chemotaxis, glucose homeostasis and modulation of iron 
homeostasis 51,52.  
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1.4.1. Cellular signalling 
BMPs binds to membrane type I and type II serine/threonine kinases receptors 
that are required for cellular signalling (Fig. 1.5) 50. This binding results in type I 
receptor phosphorylation promoted by type II receptor which recruits Smads proteins 
(fusion of names SMA and MAD from homologous proteins in C. elegans and D. 
melanogaster, respectively), that are part of the signalling cascade 50. After 
phosphorylation of restricted Smads (R-Smads) these proteins recruit common 
mediator Smads (C-Smads) to form a complex that migrates to the nucleus and 
promotes transcription of specific target genes 50,53. The signalling can be regulated at 
four levels: extracellular, in the membrane, intracellular and in the nucleus 50. 
Extracellularly, the presence of antagonists with high affinity to BMPs receptors 
prevent its binding 50. Receptors oligomerization can determine the specificity of 
signalling pathway activation 50. In the cytoplasm, the signal transmitted can be 
modulated by inhibitory Smads (I-Smads), which compete with R-Smads for binding 
type I receptors, or Smurf1 50,53. Finally, in the nucleus, the activation of specific target 
genes and their transcription can be inhibited by co-repressors 50.   
 
 
Figure 1.5 - Bone morphogenetic proteins (BMPs) signalling. BMPs binds to type I receptor (BMPR I) 
that became phosphorylated by type II receptor (BMPR II) which recruits Smads. After phosphorylation 
of restricted Smads (R-Smads) these proteins recruit common mediator Smads (C-Smads) to form a 
complex that migrates to the nucleus and promotes transcription of specific target genes. The signalling 
can be inhibited by inhibitory Smads (I-Smads), which compete with R-Smads to binding type I 
receptors. Adapted from Yamaguchi et al (2000) 53. 
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1.4.2. BMP-2 
One of the most important known functions of BMP-2 is in  bone and cartilage 
formation 54. These skeletal tissues are composed by several mesenchymal cell types, 
such as osteoblasts and chondrocytes, that differentiate in response to Core-binding 
factor subunit alpha-1/Runt-related transcription factor 2 (Cbfa/Runx2) and SRY-
related HMG box transcription factor 9 (Sox9), respectively 53,55. Regulation of 
osteoblast differentiation is coordinated by various local factors in a paracrine and/or 
autocrine manner 53. It was demonstrated that BMP-2, BMP-4 and BMP-7, are 
responsible for osteoblast and chondrocytes differentiation 53,54,56. In particular, BMP-2 
was shown to promote the expression of osteoblast phenotypic markers alkaline 
phosphatase (ALP), collagen type I and OC by increasing the expression of the 
transcription factor Cbfa/Runx2 50,53. 
 
1.4.3. BMP’s relation with VKDPs 
When Urist and colleagues first discovered BMPs, they almost immediately realise 
the tight relation between BMP and MGP, ie, BMPs and a regulator counterpart.  Since 
then, several studies were performed to prove this interaction and to understand how 
it occurs in vivo 57. Since these proteins are both synthesized by smooth muscle cells 
(SMCs), Wallin and co-workers suggested that MGP may neutralize the bone 
promoting effect of BMP-2 in the vascular wall by forming a complex between the two 
proteins and, although not proving a regulatory mechanism for MGP, their data 
confirms the binding between MGP and BMP-2 34. Later, the same group, showed that 
Ca2+ and γ-carboxylation of MGP is important for optimal BMP-2 binding to MGP and 
further demonstrated, by immunofluorescence in glandular tissues, the existence of 
MGP-BMP-2  in vivo 34,58. Boström and colleagues, by overexpressing MGP in a 
mesenchymal cell line with the capacity to differentiate in different lineages and by 
adding recombinant BMP-2 (rBMP-2), showed that MGP modulates  the capacity of 
BMP-2 to induce differentiation 59. It was suggest that MGP binding to BMP-2 probably 
prevents its interaction with cell surface receptors 59. In fact, Zebboudj and co-works 
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studies indicates that MGP inhibits BMP-2 signalling by preventing receptor binding 
and Smad1 activation 60.  
Once BMP-4 is closely related with BMP-2, Yao and colleagues hypothesized that 
the inhibitory effect MGP is not limited to BMP-2 but could also include BMP-4 61. 
Immunoprecipitation studies confirmed an interaction between the two proteins 61. It 
was also proved that, as in the case of MGP and BMP-2 interaction, calcium ions and 
Gla residues were important for the binding between MGP and BMP-4, but proline 64 
(Pro64), a conserved residue in human MGP sequence, was also critical for binding and 
inhibition of BMP-4 62.  
It was proposed a model of a regulatory pathway where MGP and BMP-2 and BMP-
4 are involved 61,63. BMP-2 and BMP-4 induce the expression of activin-like kinase 
receptor 1 (ALK1), a transforming growth factor-β (TGF-β) type I receptor associated 
with angiogenesis, that when stimulated induces the expression of MGP and vascular 
endothelial growth factor (VEGF) 61,63. MGP provides both a positive feedback, by 
enhancing the ALK1 signaling, and a negative feedback, by binding and inhibiting BMP-
2 and BMP-4 that in turn, declines ALK1 expression and activity 61,63. This pathway is 
central for vascular development, disease and homeostasis 63. BMP-7 were also 
implicated in this regulatory circuit and Yao and colleagues demonstrated that MGP 
binds and inhibits BMP-7 and BMP-4 in a similar manner 64.   
However, MGP is not the only VKDP that is related with BMP-2. Surmann-
Schmitt and colleagues have shown that GRP’s mRNA and protein levels are down-
regulated in murine chondrocytes treated with rBMP-2. Their results suggest a 
potential regulatory effect of BMP factors on GRP expression, although without 
mechanistic any data.  
 
1.5. Vascular calcification  
Vascular calcification is a disease described as being present over 5000 years ago, 
related with increased cardiovascular mortality and morbidity, and considered as a 
strong and independent risk factor for cardiovascular death 8,9. Calcification is mainly 
present in the arterial vessel wall (Fig. 1.6A) and results in reduced arterial elasticity 
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and subsequent altered hemodynamics, contributing to the development of aortic 
stenosis, cardiac hypertrophy, hypertension, heart failure, and myocardial ischemia 8. 
Within the vessel wall there are two different sites of calcification development: 
intimal and medial calcification 65. Intimal or atherosclerotic calcification (Fig. 1.6B) is 
caused by a combination of risk-factors such as hypertension, inflammation, or 
dyslipidemia, and is characterized, in early stage, by a disperse punctate form and, as 
the disease progresses, by aggregates of calcium phosphate crystals deposits 
producing larger patchy stippled crystals and associating with the necrotic region of an 
atheroma 8,66. Medial calcification (Fig.1.6C), also known as Monckeberg’s sclerosis, is 
characterized by amorphous mineral deposits along the elastin fibres of the tunica 
media which in an early stage are linear deposits that become circumferential rings of 
mineral as the disease proceeds 8,66. This type of calcification is highly associated with 
aging, CKD and diabetes mellitus 8. 
 
Figure 1.6 - Different types of vascular calcification in the arterial vessel wall. A) Healthy vessel in the 
absence of calcification. B) Intimal calcification with accumulation of calcium deposits in intima. C) 
Medial calcification with calcium deposits along the tunica media. Adapted from Willems et al (2014)8. 
 
1.5.1. Vascular calcification and VKDPs 
For decades, vascular calcification development was considered as an inevitable 
consequence of aging and disease, but it is now considered to be an active process 
involving different molecular mechanisms where clearly a great importance has been 
given to VKDPs 8,65,67. Human body fluids are supersaturated with calcium and 
phosphate but spontaneous mineralization does not normally occur due to a tight 
control by calcification inhibitors, namely MGP and eventually GRP 8,66. In the case of 
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MGP, it was demonstrated that this protein depends on its Gla residues to bind 
calcium/phosphate crystals, but when vitamin K supply is inadequate or vitamin K 
antagonists are administered, the proteins become undercarboxylated, inactive, 
resulting in arterial calcification 39. This hypothesis was proved by two independent 
studies that demonstrated the presence of poorly carboxylated MGP in calcified 
vasculature of aging rats and rats treated with warfarin, and a study in humans 
showing deposition of ucMGP in arteries from patients with atherosclerosis and 
Monckeberg’s sclerosis  31,39,58. 
Fetuin-A, an extracellular calcium-regulatory protein, is also a potent inhibitor of 
calcium-phosphate precipitation 68. Fetuin-A and MGP form a high molecular mass 
complex with calcium-phosphate mineral, named fetuin-mineral complex (FMC), that 
is considered to have a role in prevention of vascular calcification avoiding mineral 
growth and targeting it for clearance from blood  69,70. MGP γ-carboxylation appears to 
be essential for the presence of this protein in the complex 8. 
 
1.5.2. Vascular calcification and matrix vesicles 
As it occurs during osteogenesis and chondrogenesis, VSMCs release particular 
membrane structures, known as matrix vesicles (MVs), that serve as the initial nidus 
for calcium phosphate crystal deposition which promotes the onset of extracellular 
matrix calcification 8,71. Under normal conditions, MVs are loaded of inhibitory proteins 
such as fetuin-A and MGP that block hydroxyapatite nidus 8,71. However, in a calcium-
rich environment, reported in pathologies associated with increased vascular 
calcification, these membrane structures are able to calcify. At calcification sites, 
VSMCs can undergo phenotypic transition to osteoblast/chondrocyte-like cells, 
upregulating the expression of mineralization-regulating proteins, such as BMPs 
8,66,71,72. BMP-2 is a crucial factor in this transition promoting the upregulation of 
osteogenic key factors as Cbfa1/Runx2 gene, essential for osteoblast differentiation 
and bone development, that consequently leads to an osteogenic phenotype 8,73. As 
mentioned above, MGP could prevent this phenotypic transition through an 
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interaction with BMP-2 avoiding its binding to the receptors and consequently blocking 
gene transcription 59,60.  
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2. Objectives 
 
Matrix Gla protein is an established inhibitor of soft tissue calcification and, 
although still not completely understood, it is known that its inhibitory mechanism is 
regulated by antagonizing BMPs through direct protein-protein interaction. However, 
these proteins and their mechanisms of action are not enough to explain the several 
cases of pathological calcification. Gla-rich protein, the newest VKPD, has also been 
recently associated with ectopic calcification related diseases. This association, 
together with results that report a potential regulatory effect of BMP factors on GRP 
expression in murine chondrocytes, lead us to hypothesize this protein as one of the 
missing regulators involved in the inhibition of ectopic calcification. In this way, the 
major goal of this work is the study of the possible interaction between GRP and BMPs. 
To achieve our objectives we established a system of production of human 
recombinant GRP and MGP in HEK293T cells and used their conditioned media to 
perform interaction studies between these proteins and BMPs. 
Aiming at the better characterization of GRP biological role, it is also our goal to 
produce and optimize purification methods to isolate human recombinant γ-
carboxylated protein. The success of this objective will further enable us, in a near 
future, to prove our hypothesis on GRP participation on calcification-related events 
through the development of functional assays. 
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3. Methods 
 
3.1.  Cell culture 
Human embrionic kidney 293T (HEK293T) cells were cultured in Dulbecco’s 
modified eagle medium (DMEM, Invitrogen) supplemented with 10% (v/v) of heat-
inactivated foetal bovine serum (FBS, Sigma-Aldrich), 200 mM of L-glutamine 
(Invitrogen) and 1% (v/v) of penicillin/streptomycin (Invitrogen). Cell cultures were 
maintained in 5% CO2 at 37o C.  
 
3.2.  Human GRP cloning into expression vectors 
Two different constructions were prepared to produce either GRP or a fusion of 
GRP-mKate2 proteins; in both cases, complete coding sequence of GRP (alternative 
transcript F1, Fig. 1.4) was used. The complete coding sequence of human GRP was 
cloned into the expression vector pmKate2-C (where mKate2 was removed, Evrogen, 
Fig. 3.1A) and a fusion protein consisting of GRP C-terminus fused to the mkate2 N-
terminus was produced using the plasmid pmKate2-N (Evrogen, Fig. 3.1B).  
To clone human GRP into pmKate2-C, both respective fragment and plasmid were 
digested with the restriction enzymes NheI and BglII (New England Biolabs). After size-
separation onto a 1% (w/v) agarose gel and fragments purification, inserts were cloned 
into pmKate2-C using T4 DNA ligase (Fermentas) following manufacturer’s 
recommendations. The resulting construction was transformed into DH5 bacteria and 
selected positive clones were analysed by sequencing at CCMAR Sequencing Facilities. 
A similar procedure was performed to obtain the fusion construct mentioned above, to 
clone GRP into pmKate2-N, using in this case the restriction enzymes PstI e BamHI 
(New England Biolabs) taking into consideration the maintenance of an open reading 
frame for GRP-mkate2 translation. Specific primers used for the aforementioned 
cloning constructs are listed in Annex I. 
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3.3.  Production of human recombinant proteins in HEK293T cells 
HEK293T cells were seeded out in 10-cm dishes and transiently transfected using 
the calcium/phosphate method or FuGENE 6 (Promega) with 4 to 16 µg of DNA of 
interest. In the case of MGP we have used the plasmid pN-FLAG-MGP, a kind gift from 
Dr. Kristina Böstrom (UCLA, David Geffen School of Medicine, USA). According to 
experimental plan, total proteins extracts and/or conditioned media were collected. 
Conditioned media, treated with vitamin K1 (50 nM 74), were collected 48 or 72h after 
transfection and aliquots were lyophilized, while total cells extracts were obtained 
using RIPA buffer. Protein content was determined by spectrophotometry at 280 nm 
(Nanodrop 1000, Thermo Scientific) following the relation 1 U Abs280 = 1 mg/ml. 
To produce HEK293T stable clones overexpressing GRP, cells were transfected 
using the same conditions as described previously but introducing a selective pressure 
by treating transfected cells with G418 (Sigma-Aldrich) at a concentration of 400 
µg/ml. Several days after transfection, individual colonies were expanded and, besides 
collection of conditioned media and total cells extracts, total RNA were extracted as 
described by Chomczynski and Sacchi [REF]. RNA concentration was determined by 
spectrophotometry at 260 nm (Nanodrop 1000). 
 
 
 
Figure 3.1 - Plasmid constructions used to overexpress GRP and GRP-mKake2 in vitro. A) pmKate2-C-
GRPF1 (F1 stands for alternative transcript F1). B) pmKate2-N-GRPF1. Cytomegalovirus promoter; GRP 
coding sequence; mKate2 codingsequence; Kanamycin/neomycin resistance gene.  
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3.4.  Genomic DNA extraction 
To extract genomic DNA, HEK293T cells were disrupted using lysis buffer (10 mM 
EDTA, 0.05 M Tris-HCl pH 8.0, 1% (w/v) SDS) and proteinase K (10 mg/ml) and 
incubated overnight (O/N) at 50oC with gentle agitation. Genomic DNA was then 
isolated using 1V of phenol pH 8.0 with gentle agitation followed by an additional 
extraction step with phenol pH 8.0 / chloroform / isoamyl alcohol (25:24:1). After 
precipitation and ethanol washing, samples were dried and resuspended in ultrapure 
water. Centrifugations were performed for 10 min at 13 000xg. DNA concentration was 
determined by spectrophotometry at 260 nm (Nanodrop 1000). 
 
3.5.  RT-qPCR  
One microgram of total RNA treated with RQ1 RNase free DNase (Promega) was 
reverse transcribed using Moloney-murine virus reverse transcriptase (MMLV-RT), 
RNase Out (both from Invitrogen) and an oligo(dT) adapter, according to 
manufacturer’s recommendations. 
To determine which HEK293T stable clone had higher expression of GRP, 
quantitative PCR (qPCR) amplification was performed using 5 µl of cDNA (1:10 diluted 
RT) and SsoFast EvaGreen supermix (Bio-Rad) in reactions of 50 cycles. Human 
ribosomal 18S was used as a housekeeping gene for normalization. Primers used are 
listed in Annex I.  
 
3.6.  Purification of recombinant human GRP through affinity 
chromatography 
To purify the human recombinant GRP, conditioned medium from HEK293T cells 
transfected with pmKate2-C-GRP or pmKate2-N-GRP (Fig. 3.1A and B, respectively) 
were collected and centrifuged at 2 000xg, 5 min to remove cell debris and pellet down 
any dead cells. Supernatant was then centrifuged at 12 000xg for 15 min, at 4oC, to 
remove insoluble proteins and filtered before purification through affinity 
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chromatography. Briefly, the affinity column was prepared using CNBr-activated 
Sepharose 4B beads (GE Healthcare), approximately 10 ml of beads, and cross-linked 
to the rabbit polyclonal CTerm-GRP antibody (GenoGla Diagnostics). First, the column 
was equilibrated in 10 V of 10 mM Tris pH 7.5 and approximately 50 ml of diluted (1:2) 
conditioned media, in the same buffer. Conditioned media was repeatedly passed 
through the column three times. The column was then washed with 10V of 10 mM Tris 
pH 7.5 and 10 V of 10 mM Tris pH 7.5 / 500 mM NaCl. Acid and basic elutions were 
performed to fraction affinity-bounded proteins using an acid solution of 100 mM 
glycine pH 2.5 and a basic solution of 100 mM triethylamine pH 11.5. Fractions of 1 ml 
were collected and protein content was determined by spectrophotometry at 280 nm 
(Jasco V630 Spectophotometer) considering the relation 1 U Abs280 = 1 mg/ml protein. 
 
3.7. Immunoprecipitation 
 
3.7.1. Immunoprecipitation using magnetic beads 
Immunoprecipitation (IP) was performed using the Immunoprecipitation 
Dynabeads
 
Protein A Kit (Invitrogen). Antibodies, listed in Annex II, and the Dynabeads 
protein A were incubated, in a ratio of 10 µg of antibody per 50 µl of Dynabeads, for 
approximately 3 h to promote their binding, followed by incubation with the antigen 
for 1 h. For antigen preparation, two aliquots of equal volumes of each conditioned 
media containing MGP-FLAG, GRP-mKate2 and 100 ng/ml of human recombinant BMP-
2 protein (Peprotech) were mixed and incubated for 2 h. After incubation, the mixture 
was equally divided into different tubes, according to IP and respective antibody of 
interest, and incubated for 1 more hour. All incubations were performed at room 
temperature (RT), with gentle agitation. Elution was performed in 20 µl of NUPAGE 
sample buffer followed by immunoblotting as described in section 3.8. 
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3.7.2. Immunoprecipitation using protein A sepharose beads  
For this IP approach, 25 mg of protein A sepharose beads (GE Healthcare) were 
used per 50 µg of each antibody listed in Annex II. Beads were washed twice with 
ultrapure water, once with PBS and then blocked with 1 mg/ml of bovine serum 
albumin (BSA) in PBS for 1 h. After binding of antibodies, beads were washed with 
excessive PBS. Antibodies were cross-linked to protein A sepharose by adding 200 
mmol/L triethanolamine / 20 mmol/L dimethyl pimelimidate in PBS (final pH 8.6). After 
rotation for 30 min, the beads were washed twice with 200 mmol/L triethanolamine in 
PBS. The remaining reactive amino groups were quenched by addition of 50 mmol/L 
ethanolamine in PBS for 1 h. Non-cross-linked antibodies were removed by incubating 
twice with 1 M glycine pH 3 for 20 min at 56oC and washed twice with PBS, followed by 
incubation with antigen O/N. For antigen preparation, two aliquots of equal volumes 
of each conditioned media containing MGP-FLAG, GRP-mKate2 and 100 ng/ml of 
human recombinant BMP-2 were mixed and incubated for 1 h. The mixture was then 
evenly divided into different tubes, according to the antibody used and incubated O/N 
at 4ºC. Beads were washed six times with PBST, eluted three times with 100 mM 
glycine pH 2.5 and then washed again three times with PBST. To improve the binding 
yield, this incubation step was repeated twice. Cross-linked beads were stored at 4 °C 
in PBS containing 0.2 mL/L Tween-20 (PBST) to be reused. All reactions were 
performed at RT, except incubation with antigen that was performed at 4ºC; PBS was 
used at pH 7.0 unless stated otherwise.  
 
3.8.  Protein electrophoretic fractioning and immunodetection  
Aliquots of conditioned media (usually 100 µl) and total protein extracts (50-100 
µg) were size-separated onto a 4-12% (w/v) gradient polyacrylamide precast gel 
containing 0.1% (w/v) SDS (NuPage, Invitrogen) and ran at 180 V. Transfer onto a 
nitrocellulose membrane (BioRad) was performed at 80 mA for 1.5 h. Membrane was 
blocked with 5% (w/v) BSA in phosphate buffer saline tween [PBST: 15 mM NaH2PO4, 
8.1 mM Na2HPO4.2H2O, 1.45 M NaCl, pH 7.4, 0.05% (v/v) Tween20] for 3 h and 
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incubated O/N with primary antibodies, listed in Annex II, according to the protein of 
interest. Immunodetection was achieved using species-specific secondary horseradish 
peroxidase conjugated antibodies (Sigma-Aldrich) and Western Lightning Plus-ECL 
(PerkinElmer) detection system. 
 
3.9.  Total protein content detection 
After polyacrylamide gel electrophoresis (SDS-PAGE), as described in section 3.8, 
gel was washed two times for 5 min with ultrapure water and then fixed with fixing 
solution [50% (v/v) ethanol, 2% (v/v) phosphoric acid] for 2h. After fixation, gels were 
washed three times for 25 min and equilibrated with an equilibration solution [34% 
(v/v) methanol, 17% (w/v) aluminium sulphate, 2% (v/v) phosphoric acid] for 1h. Gels 
were stained with coomassie brilliant blue (CBB) G-250 [10% (w/v) sulfoacidic acid, 
10% (w/v) trichloroacetic acid, 0.2% (w/v) CBB G-250] O/N and destained with 
ultrapure water. Bands of interest were cut and analysed through LC-MS/MS at the 
Mass Spectometry Unit, Center for Neurosciences and Cell Biology/Biocant, University 
of Coimbra.  
 
3.10. Human BMP-2 cDNA amplification 
For human BMP-2 (NM_001200) coding sequence amplification, several primers 
sets were designed (Annex I) using Primer-Blast tool at NCBI. Reverse transcribed RNA 
from bone and cartilage, from either healthy individuals or osteoarthritis (OA) patients, 
was used as template for BMP-2 amplification. First and nested PCR reactions were 
performed using 5 µl of cDNA or previous PCR, respectively, different sets of primers 
and Taq DNA polymerase (Invitrogen), following manufacturer’s recommendations. 
PCR products were size-separated onto a 1% (w/v) agarose gel and selected fragments 
were purified using GFX Gel Band Purification kit (GE Healthcare), cloned into pCRII-
TOPO vector (Invitrogen) and sequenced at CCMAR Sequencing Facilities.   
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3.11. Immunocytochemistry 
HEK293T cells were cultured in 13-mm poly-Lysine pre-coated glass coverslips in 
24-well plates at a concentration of 8x104 cells per well. Cells, transiently transfected 
with pmKate2-C-GRP (expressing only GRP) or co-transfected with pN-FLAG-MGP, 
were washed two to three times with phosphate-buffered saline (PBS), fixed with 4% 
(v/v) paraformaldehyde in PBS (PFA) for 30 min, washed three times with PBS, and 
permeabilized with PBS 0.5% TritonX-100. For immunodetection, cells were incubated 
with primary antibodies diluted in ADB [1% (v/v) SFB, 0.05% (v/v) of Tween20 in PBS] 
for 1h at RT in a humidified chamber, followed by an incubation with secondary 
antibodies, also diluted in ADB, for 30 min in humidified dark chamber. Antibodies are 
listed in Annex II. Nuclei were stained with 2 µg/ml DAPI and coverslips mounted in 
ProLong Gold (both from Life Technologies). Images were obtained through stacks 
imaging using Zeiss Axio-Imager Z2 microscope at the Light Microscopy Unit, 
Department of Medicine and Biomedical Sciences, UAlg. The images result from a Z 
projection.  
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4. Results 
 
4.1. HEK293T cells express and secrete GRP-mKate2 fusion 
protein into extracellular media  
To produce human recombinant GRP, fused to mKate2 fluorescent protein, in 
order to increase protein solubility, we have started by stably transfecting HEK293T 
cells with pmKate2-N-GRP construct (mature protein with a theoretical molecular 
weight of approximately 43 kDa). After treating transfected cells with G418 for positive 
clone selection, four clones were picked and respective RNA collected to analyse GRP 
gene expression levels. Results indicate a higher gene expression level for clone 4 (Fig. 
4.1), leading us to investigate its protein levels, both extracellularly (conditioned 
media) and intracellularly (total cell extracts).  
 
Figure 4.1 - Gene expression levels of HEK293T clones overexpressing GRP. Expression levels of GRP 
gene in HEK293T stable clones (numbered 1-5) were obtained by (A) RT-PCR and quantified by (B) qPCR; 
18S was used as a housekeeping to normalize expression. 
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Western blot results indicate that either GRP-mKate2 fusion protein is not being 
translated, or that its levels are too low because it was not detected in conditioned 
media nor in total cell extracts (data not shown). In fact, the absence of protein 
translation can be explained by the presence of SV40 large T antigen in HEK293T cells. 
The generation of stable cell lines expressing the SV40 large T antigen is very difficult 
with any plasmid that contains the SV40 promoter, which is the case of pmKate2-N, 
once that SV40 large T antigen induces DNA replication at the SV40 promoter in the 
vector sequence. 
To continue our goal of producing human recombinant GRP protein, we decided to 
perform transient transfections of HEK293T cells with either pmKate2-N-GRP or 
pmKate2-C-GRP plasmids, to produce recombinant GRP-mKate2 and GRP (with a 
theoretical molecular weight of approximately 17 kDa), respectively. Conditioned 
media and total cell extracts were collected from both cell cultures and analysed by 
western blot. Our results indicate that recombinant proteins were both translated and 
secreted since could be detected in culture media (Fig. 4.2A and B). In the case of GRP 
without mKate2 tag, the presence of two fragments of different sizes in conditioned 
media could be due to the presence of different GRP γ-carboxylated forms. In total cell 
extracts, a fragment with higher molecular weight than the fragments detected in 
conditioned media is, probably, an unprocessed form of GRP. 
 
Figure 4.2 - Analysis of GRP protein levels in transiently transfected HEK293T cells. HEK293T cells were 
transiently transfected with pmKate2-N-GRP or pmKate2-C-GRP plasmids and conditioned extracellular 
(Ex) and intracellular (In) media were analysed by SDS-PAGE followed by western blot. GRP-mKate2 was 
immunodetected with (A) tRFP and GRP without mKate2 tag was immunodetected with (B) CTerm-GRP. 
Relevant molecular mass markers (kDa) are indicated on the right side of the panels.   
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4.2. GRP-mKate2 is efficiently purified through a CTerm-GRP 
affinity chromatography  
To better characterize GRP biological role, functional studies, that include a 
comparison between uncarboxylated and carboxylated protein forms, are crucial. The 
system to produce GRP in E. Coli, in large quantities, is currently available in the lab, 
but provide us only with the uncarboxylated protein form. For functional comparative 
studies, is urgent to produce also the γ-carboxylated form, believed to be crucial for 
protein’s function. To achieve this goal we have decided to purify the human 
recombinant GRP or fusion GRP-mKate2 produced in HEK293T cells and secreted into 
conditioned media, by affinity chromatography. HEK293T cells transfected with 
pmkate2-N-GRP or pmkate2-C-GRP, and treated with vitamin K1, were collected and 
fractioned through an affinity column prepared using CNBr-activated Sepharose 4B 
beads cross-linked to the rabbit polyclonal CTerm-GRP antibody. Acid and basic 
elutions were performed to fraction affinity-bounded proteins. Fractions were 
collected and protein content was determined by spectrophotometry at 280 nm for 
both fusion GRP-mKate2 (Fig. 4.3A and B) and GRP without mKate2 tag conditioned 
media (Fig. 4.5). Fractions exhibiting higher absorbance levels were selected (Fig. 4.3 
and 4.4), analysed by SDS-PAGE and the protein of interest was detected using specific 
antibodies. Our results indicate that only GRP-mKate2 fusion protein was efficiently 
purified (Fig. 4.3C). This is most possibly due to its higher solubility when compared 
with GRP without mKate2 tag for which, although its absorbance levels are high, no 
signal can be detected using specific antibodies (data not shown). The γ-carboxylation 
status of purified GRP was further investigated using conformational antibodies to 
carboxylated (cGRP) and undercarboxylated (ucGRP) protein forms. Our results 
indicate that GRP-mKate2 fusion protein present in the condition media is 
undercaboxylated (Fig. 4.3C). During GRP-mKate2 conditioned media preparation we 
have obtained a pellet after centrifugation at 12 000 xg for 15 min that was also 
analysed. Importantly, SDS-PAGE and western blot results indicate the presence of 
both forms of GRP, carboxylated and undercarboxylated, which are recognized by 
ucGRP and cGRP antibodies, respectively (Fig. 4.3C), in this insoluble fraction. Due to 
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annexin 6 association to matrix vesicles, we have also investigated its presence in the 
pellet, and a positive signal at 68 kDa was detected in our western blot (Fig. 4.3C).  
 
 
Figure 4.3 - GRP-mKate2 purification through affinity chromatography. Conditioned media from 
HEK293T cells transfected with pmkate2-N-GRP was collected and fractioned through an affinity column 
with CTerm-GRP antibody. (A) Acid and (B) basic elution was performed to fraction affinity-bounded 
proteins and protein content of each fraction collected was determined by spectrophotometry at 280. 
(C) Fractions exhibiting higher absorbance levels (red points) and conditioned media insoluble fraction 
(pellet) were size-separated by SDS-PAGE and the protein of interest was immunodetected with  CTerm-
GRP by western blot. The γ-carboxylation status of purified GRP was investigated using 
undercarboxylated (ucGRP) and carboxylated (cGRP)antibodies, respectively; the presence of annexin 6 
(ANXA6) was also investigated. Relevant molecular mass markers (kDa) are indicated on the right side of 
the panels.   
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Figure 4.4 - GRP purification through affinity chromatographyy. Conditioned media from HEK293T cells 
transfected with pmkate2-C-GRP construct were collected and fractioned through an affinity column 
with the CTerm-GRP antibody. (A) Acid and (B) basic elution was performed to fraction affinity-bounded 
proteins and protein content of each fraction collected was determined by spectrophotometry at 280. 
Fractions exhibiting higher absorbance levels (red points) were size-separated and the presence of 
protein of interest was investigated by western blot using the CTerm-GRP although no positive signal 
was obtained (data not shown).  
 
4.3. Human MGP recombinant protein is majorly retained 
intracellularly or in the matrix of HEK293T cells 
To overexpress human MGP, HEK293T cells were transiently transfected using pN-
FLAG-MGP construct with a respective translated protein with a theoretical molecular 
weight of approximately 14 kDa. Both total cell extracts and conditioned media 
obtained from this experiment were analysed by SDS-PAGE and western blot. Results 
indicate that most of the protein produced is retained intracellularly or in the ECM, 
while protein in conditioned media is almost barely detected (Fig. 4.5). This result 
indicates that optimizations are still required, such as altering the amount of DNA for 
transfection and/or using different transfection agents, adjusting the time point for 
total cell extracts and conditioned media collection or even using a different protein 
tag that might increase the solubility of the fusion product. 
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Figure 4.5 - MGP overexpression in HEK293T cells. pN-FLAG-MGP were transiently expressed in 
HEK293T cells and intracellular (In) and extracellular (Ex) conditioned media were analysed by SDS-PAGE 
and western blot. MGP was immunodetected with M2 an antibody specific for F tag. Relevant molecular 
mass (kDa) is indicated on the left side of the panel.   
 
4.4. Identification of a novel BMP-2 alternative transcript   
 To determine a possible interaction between BMP-2 and GRP as described for 
MGP, we have started by cloning the human BMP-2 transcript corresponding to the 
complete coding sequence (CDS) to further use it to overexpress this protein in 
HEK293T cells. Several pairs of primers were designed to perform both first and nested 
PCR reactions and bone and cartilage samples from healthy and OA individuals were 
used as a template. We were not successful on the amplification of BMP-2 complete 
CDS and instead we have identified a novel fragment of approximately 1000 bp from 
cartilage of an OA patient (Fig. 4.6). This fragment was confirmed, through sequencing, 
to be an alternative transcript of the human BMP-2 gene that had not been described 
previously (GenBank identification number 4670498). This alternative transcript 
exhibits the loss of exon 2, coding for the initial ATG, resulting in a small truncated 
protein, if translated. Since full CDS of human BMP-2 was not obtained within this 
project, we have decided to use a commercial human recombinant protein for further 
protein-protein interaction studies. 
 
Figure 4.6 - BMP-2 alternative transcript identification. A fragment of approximately 1000 bp 
corresponding to a novel alternative transcript (GenBank identification number 4670498) was identified 
in cartilage of an OA patient. Relevant molecular mass (bp) is indicated on the left side of the panel. 
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4.5. GRP co-immunoprecipitates with BMP-2 
To study a possible interaction between human BMP-2, GRP and MGP we have 
performed IP assays. We have started by mixing equal amounts of conditioned media 
from HEK 293T cells overexpressing i) GRP-mKate2, ii) MGP-FLAG while iii)  100 ng/ml 
of human recombinant BMP-2 was also added to the media. In parallel, we have 
analysed recombinant BMP-2 by SDS-PAGE and western blot to determine 
electrophoretic migration pattern and optimize conditions for detection. Two bands 
were detected at 25 and 15 kDa corresponding to dimeric and monomeric forms of 
BMP-2, respectively (Fig. 4.7A). GRP-mKate2 was first captured with tRFP antibody, 
specific for mKate2, and the co-immunoprecipitated (co-IP) proteins (IP tRFP) were 
analysed by western blot using a specific antibody for BMP-2/4. The results show that 
BMP-2 co-immunoprecipitate with GRP (Fig. 4.7B) pointing to an interaction between 
the two proteins.  
 
 
Figure 4.7 - Co-immunoprecipitation of GRP and BMP-2. Conditioned media from cells transfected with 
pmKate2-N-GRPF1 and pN-MGP-FLAG to which 100 ng/ml of recombinant BMP-2 was added, were used 
to perform immunoprecipitation assays. A) 50 ng of recombinant BMP-2 was analysed by SDS-PAGE and 
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western blot to determine the appropriate amount for detection and electrophoretic migration pattern. 
Immunodetection was performed using BMP-2/4 antibody. GRP-mkate2 was captured with tRFP 
antibody and the co-immunoprecipitated proteins were analysed by western blot using BMP-2/4 
antibody. BMP-2 was captured with corresponding antibody and the immunoprecipitated proteins 
analysed by western blot using B) CTerm-GRP and C) tRFP antibodies. Relevant molecular mass (kDa) 
markers are indicated on the left side of panels. 
 
 
On the other hand, when these co-IP proteins (IP tRFP) were analysed by western 
blot using CTerm-GRP and tRFP antibodies, positives bands of different sizes were 
detected. Bands of approximately 43 and 15 kDa were identified with CTerm-GRP 
antibody (Fig. 4.7C) while tRFP detects 43 and 25 kDa bands (Fig. 4.7D). Based on 
these results we hypothesized that fragments at approximately 25 and 15 kDa, 
respectively, could arise from proteolytic cleavage of 43 kDa fusion GRP-mKate2 (Fig. 
4.8). To confirm this hypothesis, conditioned media from HEK293T cells overexpressing 
GRP-mKate2 was immunoprecipitated with tRFP antibody. The IP proteins were size-
separated and total proteins were stained with CBB G-250 (Fig. 4.9). Bands 
corresponding to 43 and 25 kDa were analysed through LC-MS/MS and the identity of 
GRP-mKate2 at 43 kDa and only mKate2 at 25 kDa was confirmed. These data are 
consistent with our previously results (Fig. 4.2A). 
 
 
Figure 4.8 - Putative proteolytic cleavage of GRP-mKate2. (A) Putative proteolytic cleavage site in GRP-
mKate2 fusion protein and the resulting fragments. (B) Our hypothesis of fragments’ recognition using 
CTerm-GRP and tRFP antibodies, according to putative proteolytic cleavage.     
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Figure 4.9 – Co-IP and SDS-PAGE analysis for proteins identification. Immunoprecipitated proteins 
were size-separated through SDS-PAGE and gel was stained with CBB G-250. Bands of interest were cut 
and analysed by LC-MS/MS. Identification results confirm the band between 50 and 37 kDa as GRP-
mKate2 whereas the band at 25 kDa was identified as mKate2. Relevant molecular mass (kDa) markers 
are indicated on the left side of panel. 
 
 
BMP-2 was captured using its specific antibody (IP BMP-2) and the co-IP proteins 
were analysed by western blot using CTerm-GRP and tRFP antibodies. In both cases, a 
band at 15 kDa was detected, suggesting that the interaction between BMP-2 and GRP 
could be more efficient with GRP than with the fusion protein (Fig. 4.7).  
For both IP assays, co-IP proteins were also analysed using M2 antibody, specific 
for the FLAG tag but no signal was detected (data not shown). Immunoprecipitation 
with rabbit IgG was always used as a control and in both cases the results were 
negative (Fig. 4.7B, C and D). 
 
 
4.6. Co-localization of GRP with MGP 
In order to demonstrate a possible interaction between GRP and MGP, HEK293T 
cell were transiently co-transfected with pmKate2-C-GRP and pN-FLAG-MGP.   
Immunofluorescence assays were performed 24h after transfection with CTerm-GRP 
and M2 antibodies. Results show overlapping signal of both MGP and GRP (Fig. 4.10A). 
To determine GRP intracellular localization, immunofluorescence experiments 
were performed 24h after transient transfection of these cells with pmKate2-C-GRP 
using CTerm-GRP and pan-cadherin antibodies. Colocalization of GRP with endogenous 
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pan-cadherin, specific for cellular membrane, indicates a predominant localization of 
GRP in this cellular structure (Fig. 4.10B). 
 
 
Figure 4.10 - GRP co-localizes with MGP in co-transfected HEK293T cells. HEK293T cells were 
transiently co-transfected with pmKate2-C-GRP and pN-FLAG-MGP or transfected with pmKate2-C-GRP 
only. (A) GRP detection was achieved using the CTerm-GRP antibody and secondary anti-rabbit-Alexa 
488 (green), while MGP was detected with FLAG-tag M2 antibody and anti-mouse-Alexa 594 (red). (B) 
GRP (green) co-localizes with pan-cadherin (red) indicating its presence in cellular membrane. Scale bar 
represents 20 µm.    
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5. Discussion 
 
Gla-rich protein is the newest member of the VKDP family and is characterized by 
the highest density of Gla residues known for their capacity to bind calcium 28. It is 
known that γ-carboxylation of VKDPs is, in most cases, a determining factor for their 
proper function 2. In particular, it has been suggested that human GRP carboxylation is 
a determinant factor for GRP role in ectopic calcification inhibition. The presence of 
Gla residues in its sequence has been based on its high sequence similarity with 
sturgeon GRP, previously shown to be γ-carboxylated by amino acid analysis, and the 
identification of specific domains and motifs conserved in other VKDPs 28. More 
recently, using conformational antibodies specific to cGRP and ucGRP, it was also 
demonstrated that the presence of these protein forms could be further associated to 
healthy or pathological conditions 45,47. 
Since only small amounts of protein can be purified from human tissues or 
biological fluids, genetic engineering become important to produce a functional 
recombinant protein, as identical as possible to the human form and for that,  all 
possible post-translational modifications should be considered 75. This opens up a 
variety of opportunities of producing proteins with therapeutic applications, such as in 
diabetes, end-stage renal disease and inborn errors of metabolism 75. Escherichia coli 
(E. Coli) is widely used to produce recombinant proteins due to its great advantages, 
such as fast growth kinetics and easy transformation with exogenous DNA, but this 
system fails when eukaryotic post-translational modifications are required 76. Given 
the need of GRP to be γ-carboxylated to become functional, we developed a protocol 
to purify this protein through affinity chromatography using conditioned media from 
HEK293T cells overexpressing GRP or GRP-mKate2. Our purification was much more 
efficient in the case of GRP-mKate2 fusion protein, probably due to an increased 
solubility conferred by the larger mKate2 that is usually used to increase solubility of 
insoluble proteins. However, the purified protein obtained was mostly 
undercarboxylated, even treating cells with vitamin K1, suggesting that either vitamin 
K could have not been uptaken by these cells or the machinery needed for γ-
carboxylation could have not been fully functional in HEK293T cells. The requirement 
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of several protein factors involved in γ-carboxylation, such as GGCX and VKOR, 
probably hampered the production and secretion of this VKDP as previously described  
28. Stoichiometry of all components has also been described to be a determinant factor 
for the efficiency of this process 28. Since this was our first approach, conditions still 
need to be optimized, therefore, in order to improve the γ-carboxylation status of GRP; 
for example, the concentration of vitamin K1 should be optimized and VKOR could be 
simultaneously overexpressed 77. Nevertheless, Rafael and colleagues demonstrated 
that γ-carboxylated GRP is produced in this human cell system 45 and their results also 
point to another possibility that might explain our system. It is possible that we have 
mainly purified undercarboxylated GRP due to its higher solubility while its γ-
carboxylated counterpart, being more insoluble, is mainly detected in an insoluble 
fraction of conditioned media, pelleted down by centrifugation.   
Matrix vesicles are membrane structures known to be responsible for the onset of 
calcification but under normal conditions, ie low Ca2+ levels, are enriched in 
calcification inhibitors 71. Since annexin 6 has been associated with MVs, we have 
investigated its presence in this insoluble fraction of condition media 71. Codetection of 
annexin 6 and GRP in the same insoluble fraction, further suggests that this protein 
could be incorporated in vesicles and released into to the extracellular mediua via 
MVs, as previously demonstrated for MGP, pointing to a possible role of GRP as a 
calcification regulator through involvement into MVs biogenesis and mineralization 
competence 71,78.   
Matrix Gla protein is widely accepted as an inhibitor of soft tissue calcification 
being involved in several related human pathologies, but the absence of calcification in 
the case of Keutel syndrome, where mutations on MGP gene are present, suggests the 
involvement of alternative calcification regulators 40. It is our hypothesis that GRP 
could be one of these missing regulators involved in the inhibition of calcification in 
soft tissues, once this protein was also found to be associated with ectopic calcification 
in human skin, vasculature and cartilaginous tissues 45,46.  
Although the mechanism by which these proteins inhibit calcification is still not 
completely understood, for MGP it was proposed that this inhibition is regulated by 
BMPs, potent inducers of bone formation in both skeletal and vascular tissues 34. As it 
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has been mentioned previously, distinct studies have confirmed the direct protein-
protein interaction between BMPs and MGP involving its Gla residues. Moreover, 
BMP-2 was also proposed to be a negative regulator of GRP by down-regulating its 
gene expression and protein production in murine chondrocytes 41. Given these 
previous data on MGP-BMP-2 interaction and BMP-2 effect on GRP gene regulation, 
we have focused in testing the relevance of GRP in calcification inhibition via 
interaction with BMP-2. To further investigate these possibilities, we performed IP 
assays with conditioned media from HEK293T cells overexpressing MGP and GRP, to 
which recombinant BMP-2 was added. Our results demonstrate that BMP-2 co-
immunoprecipitates with GRP, further indicating that GRP could be, in fact, a regulator 
involved in the inhibition of ectopic calcification and that its mechanism of action, as in 
MGP, could be by an interaction with BMP-2.      
The identification, by LC-MS/MS, of two fragments with 43 and 25 kDa, 
corresponding to GRP-mKate2 and to mKate2, respectively, confirm our hypothesis 
that a proteolytic cleavage is most possibly occurring in the GRP-mKate2 fusion 
protein. This cleavage will probably result in a third fragment of 15 kDa corresponding 
to GRP. In fact, when BMP-2 is captured with the corresponding antibody and analysed 
with CTerm-GRP and tRFP antibodies, a positive signal at 15 kDa is detected. These 
results suggest that the interaction between GRP and BMP-2 could be more efficient 
with the 15 kDa protein further indicating that the fusion with mKate2 could result in a 
loss or a decrease of protein’s functionality, probably hampering accessibility for BMP-
2 binding site.  
Immunoprecipitated proteins were also analysed using M2 (FLAG tag specific) 
antibody and no signal was detected. Levels of available protein in conditioned media 
are most possibly not enough to co-immunoprecipitate with BMP-2, as it has been 
previously demonstrated 59,60. The absence of a positive signal for MGP could be 
explained by: i) poor solubility of this protein; ii) protein could be trapped in MVs and, 
in fact, its presence in these structures has been previously demonstrated in VSMCs-
derived MVs 79; or iii) most of the protein is retained in the ECM or even iv) inside the 
cell. Thus, we were unable to conclude on a putative MGP-GRP interaction. In 
conclusion, to achieve this goal, several optimization tests must be further performed: 
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amount of DNA for transfection and different transfection agents, time point for total 
cell extracts and conditioned media collection, MGP’s fusion with a larger protein to 
overcome solubility issues, as suggested by our results that show higher solubility for 
GRP-mKate2 in comparison with GRP without mKate2 tag.  Nevertheless, the existence 
of an interaction between GRP and BMP-2 in the absence of MGP, suggests an 
interesting potential role for GRP-BMP-2 interaction, apparently independent of MGP.  
An immunocytochemistry approach was used to investigate the interaction 
between GRP and MGP and to determine its subcellular localization. For that, HEK293T 
cells were transiently co-transfected with pmKate2-C-GRP and pN-FLAG-MGP or with 
pmKate2-C-GRP. Since immunofluorescence was performed 24 h after transfection, it 
is conceivable that both proteins were still intracellularly localized. This is consistent 
with results from Rafael and co-workers showing that GRP secretion increased from 48 
h to 72 h after transfection and demonstrating that GRP secretion in this cell system is 
time-dependent 45. Our results showing co-localization of GRP with endogenous pan-
cadherin indicate that GRP was most possibly following a membrane-dependent 
secretory pathway. Co-localization of GRP and MGP signals, suggests that both 
proteins could interact with each other or, at least, share the same subcellular 
localization.  
Cardiovascular disease is one of the major causes of death worldwide, thus efforts 
must be made to decrease this mortality rate. Since vascular calcification is a high risk 
condition and VKDPs, namely MGP and GRP, have been associated with ectopic 
calcification-related pathologies, we should try to better understand their molecular 
mechanism of action. This work contributes to further unveil the role of GRP in 
calcification’s regulation, by pointing to the interaction with BMP-2. Moreover, this 
interaction seems to be independent of MGP leading us to hypothesize that it can act 
as an alternative to MGP, although further functional studies must be sought to clarify 
this subject. Additionally, given the association of GRP with vascular calcification, and 
other calcification-related diseases such as osteoarthritis and certain cancers, the data 
presented in this report will further contribute to the establishment of GRP as an 
additional biomarker for prognostic and diagnostic of ectopic calcification status. 
Moreover, the discovery of potential GRP interaction partners like BMPs, known to be 
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involved in osteogenesis, and the study of its mechanism of action, will open new 
perspectives for treatment of diseases in need of alternatives.  
 
 
Perspectives 
 
41 
 
 
6. Perspectives 
 
Now that an interaction between GRP and BMP-2 was demonstrated, it is 
necessary to understand if this is a direct or indirect event. In a future work we are 
interested in identifying GRP additional interacting partners and while further tests 
must be performed to clarify if the binding between GRP and BMP-2 is independent of 
the presence of MGP, as our results suggests (Fig. 6.1). To further elucidate the 
regulatory mechanisms underlying this interaction, we are interested in: i) investigate 
if this interaction is dependent of the presence of Ca2+; ii) what is the relevance of 
GRP’s γ-carboxylation; and iii) which residues are involved in the binding between 
these two proteins. It is also crucial to understand the biological role of this 
interaction. Since BMP-2 is known by its capacity to differentiate cells into an 
osteogenic lineage, we can further investigate if GRP modulates this differentiation 
capacity. Additionally, we can perform colocalization of GRP and BMP-2 in human 
tissues to demonstrate this interaction in vivo and comparison between pathological 
and healthy tissues will help to demystify the mechanism of action of GRP, 
contributing to the evaluation of its potential as a biomarker.  
 
 
Figure 6.1 - Proposed model of GRP and BMP-2 interaction. Our results demonstrate an interaction 
between GRP and BMP-2. In a future work we are interested in (A) identify additional interacting 
partners and (B) clarify the role of MGP in this interaction.   
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Annex I – Primers for PCR amplification  
 
 Primer Sequence (5’-3’) Purpose 
SV40 large T 
antigen 
SV40-01FW 
 
TGGAATGTGTGTCAGTTAGGGTGTGGAA PCR 
SV40-02RV GGCGGGACTATGGTTGCTGACTAATTGA 
GRP HuGRP-Ex3-01FW GTCCCCCAAGTCCCGAGATGAGG 
 
RT-qPCR 
HuGRP-qPCR-Ex4R CCTCCACGAAGTTCTCAAATTCATTCC 
HuGRP_mKate2_PstI
_Fw 
GACTACCTGCAGCGCCACCATGACTTGGAGACA
GGCCGTCC 
Cloning into 
pmKate2C 
HuGRP_mKate2_Bam
HI_Rv 
gttataGGATCCGTGTGGTGGCGGTTGTAGAGAT
A 
HuGRP_pmKate2_ou
t_NheI 
GACTACGCTAGCCGCCACCATGacttggagacaggc
cgtcctgc 
Cloning into 
pmKate2N 
HuGRP_ 
pmKate2_out_BglII 
gttataAGATCTAggatgccaatggtgctacaagct 
Ribosomal 18S Hu18S-RT-01FW GGAGTATGGTTGCAAAGCTGA RT-qPCR 
Hu18S-RT-02RV ATCTGTCAATCCTGTCCGTGT 
BMP-2 HuBMP2-01FW TTTCAATGGACGTGTCCCCG RT-PCR 
HuBMP2-02FW TGCTTCTTAGACGGACTGCG 
HuBMP2-03RV ACTTCATGTGCTGGGGTTGAA 
HuBMP2-04RV AAGCACTTTGCCAGAGTAACCT 
HuBMP2-05FW GCGTGAAAAGAGAGACTGCG 
HuBMP2-07FW ACGGACTGCGGTCTCCTAAA 
HuBMP2-08RV ATTAAAGTGTCAACTGGGGTGGG 
HuBMP2-09FW CAGGTCCTTTGACCAGAGTTTTTC 
HuBMP2-10FW CCTTTGACCAGAGTTTTTCCATGT 
HuBMP2-11FW CAAAGAAAAGGAACGGACATTCGG 
HuBMP2-12RV TTTGTTTTCCCAACTTCTTTTCGT 
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Annex II – List of antibodies used in this report 
 
Protein Primary antibody Secondary antibody Purpose Size 
Annexin 6  ANXA6 (SantaCruz) 
1:200 
Anti-mouse 
1:100 000 
 
WB 68 kDa 
α-Smooth 
muscle actin 
(ASMA) 
ASMA (SantaCruz) 
1:50/1:100 
A11062 – Alexa 594 
anti-mouse 
1:500 
IF 42 kDa 
GM130 GM130 (SantaCruz) 
1:25/1:50 
A11062 – Alexa 594 
anti-mouse 
1:500 
IF 112 kDa 
 
 
 
GRP 
CTerm-GRP 
(GenoGla) 
5 µg/ml 
Anti-rabbit 
1:70 000 
A21441 – Alexa 488 
anti-rabbit 
1:250 
WB, IF 10 kDa 
UCMA (SantaCruz) 
1:500 
Anti-donkey 
1:50 000 
WB 10 kDa 
cGRP (GenoGla) 
1:1000 
Anti-chicken 
1:100 000 
WB 10 kDa 
ucGRP (VitaK) 
1:2000 
Anti-mouse 
1:100 000 
WB 10 kDa 
GRP-mKate2N tRFP (Evrogen) 
0,2 µg/ml (WB) 
1 µg/µl (IP) 
Anti-rabbit 
1:70 000 
WB, IP 40 kDa 
MGP cMGP (IDS) 
1:1000 
Anti-mouse 
1:100 000 
WB 14 kDa 
MGP-FLAG M2 (Sigma-Aldrich) 
10 µg/ml (WB) 
1:25/1:50/1:100 (IF) 
Anti-mouse 
1:100 000 
WB, IF 13 kDa 
Rabbit IgG IgG (SantaCruz) 
1 µg/µl  
Anti-rabbit 
1:70 000 
IP 25 kDa 
rBMP-2/4 BMP-2/4 (SantaCruz) 
1:100 
Anti-mouse 
1:100 000 
WB 25/36 kDa 
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pan-Cadherin pan-Cadherin 
(SantaCruz) 
A11062 – Alexa 594 
anti-mouse 
IF 135 kDa 
 
